MAPK regulation and caspase activation are required in DMNQ S-52 induced apoptosis in Lewis lung carcinoma cells

Cancer Letters

Volumn 233, Issue 1, 2006, Pages 57-67

  Lee, Soo Jin ^a,b,c   Sakurai, Hiroaki ^c   Koizumi, Keiichi ^c   Song, Gyu Yong ^a,d   Bae, Yong Soo ^e   Kim, Hyung Min ^a   Kang, Kyung Sun ^f   Surh, Young Joon ^g   Saiki, Ikuo ^a,c   Kim, Sung Hoon ^a  

^a Kyung Hee University   (South Korea)

^b Department of Computer and Electronic Physics   (South Korea)

^c UNIVERSITY OF TOYAMA   (Japan)

^d Chungnam National University   (South Korea)

^e Sungkyunkwan University   (South Korea)

^f Seoul National University   (South Korea)

^g Seoul National University   (South Korea)

Author keywords

Apoptosis; Caspases; DMNQ S 52; Immunohistochemistry; LLC cells; MAPK

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 1,4 NAPHTHOQUINONE DERIVATIVE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 (1 HYDROXYIMINO 4 METHYLPENTYL) 5,8 DIMETHOXY 1,4 NAPHTHOQUINONE S 52; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ANTINEOPLASTIC AGENT; BENZYLOXYCARBONYLASPARTYLGLUTAMYLVALYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE INHIBITOR; CYCLINE; DMNQ S 52; DNA NUCLEOTIDYLEXOTRANSFERASE; DOXORUBICIN; LIPOCORTIN 5; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN INHIBITOR; PROTEIN P38 INHIBITOR; STRESS ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GRAFT; CANCER INHIBITION; CARCINOMA CELL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MOUSE; NICK END LABELING; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, LEWIS LUNG; CASPASES; CELL PROLIFERATION; ENZYME ACTIVATION; FEMALE; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; NAPHTHOQUINONES;

ANIMALIA; MURINAE;

EID: 32244447545     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.02.042     Document Type: Article

References (28)

1. S.S. Bacus, A.V. Gudkov, M. Lowe, L. Lyass, Y. Yung, and A.P. Komarov Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53 Oncogene 20 2001 147 155
2. Y. Jing, K. Nakaya, and R. Han Differentiation of promyelocytic leukemia cells HL-60 induced by daidzein in vitro and in vivo Anticancer Res. 13 1993 1049 1054
3. M. Watabe, Y. Masuda, S. Nakajo, T. Yoshida, Y. Kuroiwa, and K. Nakaya The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells J. Biol. Chem. 271 1996 14067 14072
4. G.H. Lai, Z. Zhang, and A.E. Sirica Celecoxib acts in a cyclooxygenase-2-independent manner and in synergy with emodin to suppress rat cholangiocarcinoma growth in vitro through a mechanism involving enhanced Akt inactivation and increased activation of caspases-9 and -3 Mol. Cancer Ther. 2 2003 265 271
5. Y. Ozaki, A. Ohno, Y. Saito, and M. Satake Accelerative effect of shikonin, alkannin and acetylshikonin on the proliferation of granulation tissue in rats Biol. Pharm. Bull. 17 1994 1075 1077
6. Y. Tanaka, and T. Odani Pharmacodynamic study on "Shiunko": antibacterial effect of "Shiunko" Yakugaku Zasshi 92 1972 525 530
7. S. Tanaka, M. Tajima, M. Tsukada, and M. Tabata A comparative study on anti-inflammatory activities of the enantiomers, shikonin and alkannin J. Nat. Prod. 49 1986 466 469
8. U. Sankawa, Y. Ebizuka, Y. Miyazaki, Y. Isomura, and H. Otsuka Anti-tumor activity of shikonin and its derivatives Chem. Pharm. Bull. (Tokyo) 25 1997 2392 2395
9. G.Y. Song, Y. Kim, Y.J. You, H. Cho, and B.Z. Ahn Naphthazarin derivatives (VI): synthesis, inhibitory effect on DNA topoisomerase-I and antiproliferative activity of 2- or 6-(1-oxyiminoalkyl)-5,8-dimethoxy-1,4- naphthoquinones Arch. Pharm. (Weinheim) 333 2000 87 92
10. G.Y. Song, Y. Kim, Y.J. You, H. Cho, and B.Z. Ahn Naphthazarin derivatives (VII): anti-tumor action against ICR mice bearing ascitic S-180 cells Arch. Pharm. Res. 24 2001 35 38
11. S.H. Kim, I.C. Kang, T.J. Yoon, Y.M. Park, K. Kang, G.Y. Song, and B.Z. Ahn Anti-tumor activities of a newly synthesized shikonin derivative, 2-hyim-DMNQ-S-33 Cancer Lett. 172 2001 171 175
12. K. Ogawa, Y. Yamada, K. Kishibe, K. Ishizaki, and Y. Tokusashi Beta-catenin mutations are frequent in hepatocellular carcinomas but absent in adenomas induced by diethylnitrosamine in B6C3F1 mice Cancer Res. 59 1999 1830 1833
13. Y. Ohnishi, T. Sakamoto, H. Fujii, F. Kimura, J. Murata, and K. Tazawa Characterization of a liver metastatic variant of murine colon 26 carcinoma cells Tumour Biol. 18 1997 113 122
14. M. Ishiyama, H. Tominaga, M. Shiga, K. Sasamoto, Y. Ohkura, and K. Ueno A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet Biol. Pharm. Bull. 19 1996 1518 1520
15. D.L. Vaux, S. Cory, and J.M. Adams Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells Nature 335 1988 440 442
16. J.B. Baell, and D.C. Huang Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs Biochem. Pharmacol. 64 2002 851 863
17. M. Los, M. Mozoluk, D. Ferrari, A. Stepczynska, C. Stroh, and A. Renz Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling Mol. Biol. Cell 13 2002 978 988
18. A. Matsuzawa, and H. Ichijo Molecular mechanisms of the decision between life and death: regulation of apoptosis by apoptosis signal-regulating kinase 1 J. Biochem. 130 2001 1 8
19. Z. Xia, M. Dickens, J. Raingeaud, R.J. Davis, and M.E. Greenberg Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis Science 270 1995 1326 1331
20. M.D. Jacobson, M. Weil, and M.C. Raff Programmed cell death in animal development Cell 88 1997 347 354
21. S.H. Kaufmann, and W.C. Earnshaw Induction of apoptosis by cancer chemotherapy Exp. Cell Res. 256 2000 42 49
22. M. Bamford, G. Walkinshaw, and R. Brown Therapeutic applications of apoptosis research Exp. Cell Res. 256 2000 1 11
23. L. Peng, H. Jiang, and C. Bradley Annexin V for flow cytometric detection of phosphatidylserine expression on lymphoma cells undergoing apoptosis Hua Xi Yi Ke Da Xue Xue Bao 32 2001 602 604
24. X. Liu, C.N. Kim, J. Yang, R. Jemmerson, and X. Wang Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c Cell 86 1996 147 157
25. M. Enari, H. Sakahira, H. Yokoyama, K. Okawa, A. Iwamatsu, and S. Nagata A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD Nature 391 1998 43 50
26. X. Luo, I. Budihardjo, H. Zou, C. Slaughter, and X. Wang Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors Cell 94 1998 481 490
27. T.S. Lewis, P.S. Shapiro, and N.G. Ahn Signal transduction through MAP kinase cascades Adv. Cancer Res. 74 1998 49 139
28. N.L. Johnson, A.M. Gardner, K.M. Diener, C.A. Lange-Carter, J. Gleavy, and M.B. Jarpe Signal transduction pathways regulated by mitogen-activated/ extracellular response kinase kinase induce cell death J. Biol. Chem. 271 1996 3229 3237